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SUMMARY
The human oncogene JUN encodes a component of the AP-1 complex and is consequently involved
in a wide range of pivotal cellular processes, including cell proliferation, transformation, and apopto-
sis. Nevertheless, despite extensive analyses of its functions, it has never been directly involved in
a human cancer. We demonstrate here that it is highly amplified and overexpressed in undifferenti-
ated and aggressive human sarcomas, which are blocked at an early step of adipocyte differentia-
tion. We confirm by cellular and xenograft mouse models recapitulating these sarcoma genetics
that the failure to differentiate is dependent upon JUN amplification/overexpression.INTRODUCTION
Undifferentiated soft-tissue sarcomas are the most fre-
quent malignant mesenchymal tumors in adults. Patients
with these tumors have a poor prognosis, with a 5 year
survival rate of around 60%. We have previously shown
that a subgroup of these tumors exhibited constant high-
level amplification of the 12q14 chromosome region en-
compassing theMDM2 locus and theCDK4 locus (Chibon
et al., 2002; Coindre et al., 2003)—genetic characteristics
strongly reminiscent of those observed in well-differenti-
ated liposarcoma (WDLPS), an adipocytic tumor with good
prognosis (Forus et al., 1993; Khatib et al., 1993). In undif-
ferentiated sarcomas, however, the 12q amplification is
always associated with amplification of either 6q23 or
1p32, a feature never observed in WDLPS, except in their
undifferentiated relapses. This suggests that these undif-
ferentiated tumors might correspond to undifferentiated
liposarcomas, and that lack of differentiation could be re-lated to secondary amplification of certain target genes in
the 1p32 or 6q23 chromosome bands (Chibon et al., 2002;
Coindre et al., 2003; Heidenblad et al., 2006).
We recently demonstrated that 6q23 amplifications
likely targetMAP3K5, a gene encoding a protein in the JNK
signaling pathway (Chibon et al., 2004). Here, we demon-
strate that the target of 1p32 amplifications is the JUN
oncogene, and that overexpression of this gene closely
correlates with the undifferentiated state of the tumors.
This oncogene, cellular homolog of the v-Jun avian sar-
coma virus 17, was isolated in 1987 (Bohmann et al.,
1987) and more precisely characterized in 1988 (Angel
et al., 1988; Hattori et al., 1988). It encodes a component
of the AP-1 complex and is consequently involved in a wide
range of pivotal cellular processes, including cell prolifer-
ation, transformation, and apoptosis (Shaulian and Karin,
2002). Nevertheless, despite extensive analyses of its
functions, it had previously never been directly involved
in a human cancer.SIGNIFICANCE
Wehave demonstrated that amplification and overexpression of the oncogene JUN in human liposarcomas lead to
an undifferentiated and aggressive tumor phenotype. Besides the opportunity to better understand the biology of
the undifferentiated sarcomas and the connections between proliferation and differentiation in mesenchymal tu-
mors, these findings provide also a starting point for the development of new diagnostic tests for and clinical man-
agement of these aggressive human sarcomas. They provide the foundation for targeted gene therapy designed to
control these tumors. The xenograft model described here appears as a particularly efficient tool for testing new
gene-targeted drugs.Cancer Cell 11, 361–374, April 2007 ª2007 Elsevier Inc. 361
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JUN Amplification in Undifferentiated LiposarcomasRESULTS AND DISCUSSION
JUN Is the Only Known Gene in the Minimal
1p32-Amplified Region
A preliminary analysis of allelic imbalances in 1p32 micro-
satellite loci was performed on tumor DNAs obtained from
ten undifferentiated sarcomas (T1–T10) with amplified
1p32 and 12q14 regions. This allowed us to locate the
amplified 1p32 region between microsatellite markers
D1S200 and D1S499, with a putative minimal region
between D1S2869 and D1S2737 (data not shown) corre-
sponding to coordinates chr1:58372500–60938037 in
the Human May 2004 Assembly at UCSC. To refine this lo-
cation, we then designed a dedicated BAC-PAC array cor-
responding to this region. For this purpose, we selected
22 BAC-PAC clones in the putative minimal region and
15 clones in the two flanking regions, as well as 85 clones
from 6q23 and 12q14 bands. This array was then used to
analyze the ten tumors with 1p32 amplification by CGH.
Eight loci, covering 736 kb on the 1p32 region (coordi-
nates on chr1:58872559–59608936), were found ampli-
fied in all tumors (Figure 1A). A single known gene, JUN,
as well as spliced ESTs and part of a coding sequence
(FLJ10986), are located in this region, indicating that
JUN could be the target of the amplicon. Genomic ampli-
fication of the JUN locus was confirmed by fluorescence
in situ hybridization (FISH) on frozen tissue sections from
three tumors, which all had a high copy number of JUN
loci in all tumoral cells when compared to a control unam-
plified locus (Figure 1B).
JUN Is Overexpressed at the RNA and Protein Levels
in Tumors with the 1p32 Amplicon
To investigate the consequences of this genomic amplifi-
cation on the expression of JUN, the ten tumors with the
1p32 amplicon were studied by transcriptome analysis
on Affymetrix U133 Plus 2.0 microarrays. They were com-
pared to 13 tumors without 1p32 amplification on array
CGH analysis (five WDLPS with 12q14 amplification, and
eight undifferentiated sarcomas with 12q14 and 6q23 am-
plification). Relative overexpression of JUN was demon-
strated by real-time PCR analysis, with a good correlation
(R2 = 0.69) between the expression levels and the genomic
amplification levels previously observed in array CGH as-
says (Figure 2A). These data were confirmed by transcrip-
tome analysis on Affymetrix Human Genome U133 Plus
2.0 chip. The expression levels of the other amplified cod-
ing sequence (FLJ10986), as well as those of DA310828
and BG215747 ESTs, were not strictly correlated with their
genomic amplification status, suggesting that they are not
the target genes (data not shown). Total protein extracts
were analyzed by western blot of ten tumors with the
1p32 amplicon (T1–T10), three WDLPS (T11–T13), and
one tumor with 6q23 amplicon (T15). JUN protein levels
were vastly increased in tumors with JUN amplification/
overexpression, and in tumors with 6q23 amplification
(Figures 2B and 2C). Phosphorylation of JUN on serine
63 was increased in most tumors with 1p32 amplicon
and in the tumor with 6q23 amplicon (T15). Protein levels362 Cancer Cell 11, 361–374, April 2007 ª2007 Elsevier Inc.of JNK and phospho-JNK were similar in all undifferenti-
ated and well-differentiated samples (data not shown).
We next screened the tumors by using immunohisto-
chemistry to detect JUN protein overexpression on paraf-
fin-embedded tissue sections. As shown in Figure 2D, all
tumors with JUN overexpression stained strongly positive
for JUN protein, with intense labeling of the nuclei. By
contrast, JUN could not be detected in WDLPS, which
have no 1p32 amplification. These data demonstrate that
JUN amplification directly leads to its overexpression at
both the RNA and protein levels, strongly suggesting
that JUN is the target of 1p32 amplification in human
sarcomas.
Genes Involved in Terminal Adipocytic
Differentiation Are Not Activated in Tumors with JUN
Overexpression
To test the hypothesis that JUN overexpression blocks
adipogenesis, we analyzed by real-time PCR the expres-
sion levels of genes that are induced sequentially during
adipogenesis: SREBP1, C/EBPb, C/EBPa, PPARg2, LPL,
and Adipsin (Cowherd et al., 1999). The ten tumors with
JUN overexpression were compared to three WDLPS with
12q14 amplification and three undifferentiated tumors
with 12q14 and 6q23 amplification (T14–T16). As shown
in Figure 3A, SREBP1 and C/EBPb were expressed in the
three groups of tumors. By contrast, expressions of
C/EBPa and PPARg2, which are direct targets of C/EBPb,
and of LPL andAdipsinwere absent from most undifferen-
tiated tumors, and in particular from those with JUN over-
expression, suggesting that the C/EBPb transcriptional
network is impaired in poorly differentiated liposarcomas.
In agreement with our hypothesis, it is noteworthy that the
T7 tumor, which exhibits the lowest JUN amplification/
overexpression, has the highest expression levels of
SREBP1, C/EBPb, and Adipsin among the undifferenti-
ated liposarcomas. Affymetrix U133 Plus 2.0 microarrays
(Figure 3B) enabled a clear, unsupervised clustering of
the samples into two groups—tumors with 12q14 amplifi-
cation alone and those with 1p32 or 6q23 coamplifica-
tion—based on the same adipogenesis genes. Together,
these data suggest that these undifferentiated tumors
are committed to differentiate into adipocytes but that this
process is blocked by JUN overexpression at an early
step, between the induction of C/EBPa by C/EBPb.
JUN Overexpression Could Block Adipogenesis
by Interfering with C/EBPb Function
The involvement of JUN in cell proliferation is well docu-
mented. It has been shown that JUN regulates the expres-
sion and function of cell-cycle regulators: in particular, it
upregulates CCND1, EGFR, HBEGF, CSF2, and FGF7
genes and downregulates TP53, CDKN2A, and CDKN1A
genes (Fu et al., 1999; Passegue et al., 2001; Passegue
and Wagner, 2000; Schreiber et al., 1999; Shaulian et al.,
2000; Szabowski et al., 2000; Wisdom et al., 1999; Zenz
et al., 2003). Nevertheless, from the Affymetrix data,
we could not observe any significant difference in the ex-
pression levels of these genes between undifferentiated
Cancer Cell
JUN Amplification in Undifferentiated LiposarcomasFigure 1. Genomic Amplification of the JUN Locus
(A) The dedicated CGH array contains DNA from 37 BAC-PAC clones corresponding to 1p32 loci. The accession numbers of these clones, as well as
their genomic locations, are indicated at the top and at the bottom, respectively. The genomic status (ratio tumor DNA/normal DNA) of each tumor
(T1–T10) for each locus is indicated by a color code in filled squares, as defined at the bottom. The location of JUN is indicated, as well as the minimal
common region of amplification (open green box).
(B) FISH on frozen sections of tumors T2, T4, and T7. The control locus, corresponding to the telomeric locus D1Z2 on the short arm of chromosome 1,
is labeled in red (probe pBG2.8, kindly provided by Dr. P. Ambros). The JUN probe corresponds to the BAC RP11-63G10 (AL136985); genomic
amplification of this locus is observed in all samples. Scale bar, 20 mm.sarcomas with JUN overexpression and well-differenti-
ated tumors (Figure 4A). This observation suggests that
the lack of differentiation is not the consequence of a direct
induction by JUN of the cell cycle. However, it has been
previously shown that JUN can directly interact with C/
EBPb and modulate transcription of its target genes (Hsu
et al., 1994; Zagariya et al., 1998). It has also been demon-
strated that, in myxoid liposarcomas, the TLS-CHOP on-
coprotein prevents adipocyte differentiation by interfering
with C/EBPb (Adelmant et al., 1998; Ron and Habener,
1992). Moreover, a recent report showed that overexpres-
sion of DeltaFosB—one of the potential partners of JUN inthe AP-1 transcription complex—decreases adipogenesis
in cellular models by interfering with C/EBPb function, in
particular by inhibiting the induction of C/EBPa (Sabata-
kos et al., 2000). As tumors with JUN overexpression are
blocked between the induction of C/EBPa by C/EBPb,
we hypothesized that JUN could block adipogenesis by
interfering with C/EBPb. In agreement with this hypothe-
sis, genes directly induced or repressed by C/EBPb
(Akira et al., 1990; Cesi et al., 2005; Christy et al., 1991;
Friedman et al., 2004; Jurado et al., 2002; Oishi et al.,
2005; Poli et al., 1990; Sebastian et al., 2005; Tang et al.,
2004; Umayahara et al., 2002; Wu, 2003; ZaubermanCancer Cell 11, 361–374, April 2007 ª2007 Elsevier Inc. 363
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JUN Amplification in Undifferentiated LiposarcomasFigure 2. Overexpression of JUN mRNA and Protein
(A) Relative expression levels of JUN estimated by real-time PCR (in comparison to well-differentiated liposarcomas) correlate with the genomic
amplification level obtained by array CGH experiments.
(B) Immunoblotting of total protein extracts revealed by an anti-JUN antibody, and by an anti-phospho-JUN antibody. Ponceau staining is shown
at the bottom as a control for loading. Tumors with JUN locus amplification are indicated in red and T15 with 6q23 amplification in black. Three
well-differentiated tumors without JUN locus amplification are indicated in green.
(C) JUN protein levels normalized according to b-ACTIN expression.
(D) JUN immunohistochemistry performed on two well-differentiated liposarcomas (T12 and T13, left panel), and two undifferentiated sarcomas
(T1 and T3, right panel). For these tumors, a magnification is shown in an inset.et al., 2001; Zhu et al., 1995) are effectively down- or upre-
gulated in tumors with JUN overexpression, respectively
(Figure 4A). Among them, C/EBPa and PPARg2, involved
in the differentiation process, are downregulated, and
CCNA2 and PCNA, involved in the cell cycle, are upregu-
lated. These data suggest that JUN overexpression dis-
turbs the C/EBPb pathway through a direct interaction be-
tween JUN and C/EBPb proteins and could thus block
adipogenesis at two levels: by inhibiting key differentiation
factors and by activating cell-cycle genes. In order to
document this hypothesis, we performed luciferase re-
porter gene assays in NIH-3T3 cells, by cotransfection of364 Cancer Cell 11, 361–374, April 2007 ª2007 Elsevier Inc.a c/ebpb expression plasmid (pcDNA3-C/EBPb), with
a promoter reporter construct (pGL2-Id2/E) and with in-
creasing amounts of a jun expression plasmid (RSV-jun).
As shown in Figure 4B, luciferase activity regularly de-
creases when jun expression increases, demonstrating
that Id2 promoter induction by c/ebpb is disturbed by Jun
protein surexpression. It is noticeable that, whatever the
jun surexpression level, there is no variation of c/ebpb
protein, and that for 1.25 mg of jun expression vector, lucif-
erase activity is similar to that observed when no c/ebpb
expression vector is cotransfected. This result strongly
suggests that a high level of Jun protein could disturb
Cancer Cell
JUN Amplification in Undifferentiated LiposarcomasFigure 3. Expression Levels of the Main
Adipogenesis Genes in Undifferentiated
and Well-Differentiated Tumors
(A) Progression of adipocyte differentiation
steps, as well as expression timing of adipo-
genesis genes, is indicated at the top (adapted
from Cowherd et al., 1999). The various gene
expression levels were normalized as ex-
plained in the Experimental Procedures. The
tumor sample numbers are indicated on the
x axis.
(B) Affymetrix data obtained for the same set of
genes were clustered with the use of the DChip
software (average Euclidian algorithm).expression of c/ebpb target genes, probably titrating
c/ebpb protein by direct interaction.
The 3T3-L1 Cell Line Exhibits Chromosomal
Features Close to Those of Liposarcomas
As we could not establish cell lines from well-differentiated
or undifferentiated human liposarcomas, we chose to de-
velop a mouse model of liposarcomas by using the murine
3T3-L1 cell line, a preadipocytic nontumoral cell line that
has often been used to define molecular events associ-
ated with adipogenesis (Cowherd et al., 1999; Green and
Kehinde, 1975; Green and Kehinde, 1976; Green and
Meuth, 1974; Kim and Spiegelman, 1996; Shao and Lazar,1997; Yeh et al., 1995) and for which an mdm2 amplifica-
tion has been reported previously (Berberich et al., 1999).
To delineate more accurately the genomic profile of this
cell line, we performed its CGH analysis on a homemade
genome-wide mouse BAC array. Strikingly, beside the
mdm2 amplification, we detected high-level amplification
of the cdk6 locus as well as slight amplification of the
jun locus (Figure 5A). This observation prompted us to
verify by FISH these genomic amplifications. As shown
in Figure 5B, mdm2 and cdk6 loci were coamplified on
marker chromosomes or double-minute chromosomes in
all the cells analyzed. Most of them did not exhibit jun am-
plification. By contrast, around 1% of the cells harboredCancer Cell 11, 361–374, April 2007 ª2007 Elsevier Inc. 365
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JUN Amplification in Undifferentiated LiposarcomasFigure 4. JUN and C/EBPb Target Genes
(A) Expression levels of JUN and C/EBPb tar-
get genes, in 1p32 tumors compared to well-
differentiated liposarcomas. For each target
gene, the absolute normalized expression
values were obtained on Human Genome
U133 Plus 2.0 Affymetrix chips (mean of the
corresponding probe sets values). The relative
expression of these genes in 1p32 tumors ver-
sus WDLPS was calculated (ratios between the
mean values observed in the two groups of tu-
mors). JUN target genes expression levels are
not significantly different (ratios between 0.55
and 1.8), while most C/EBPb target genes
expression levels are highly modified (ratios
below 0.54 for the genes upregulated by
C/EBPb, and ratios greater than 2.3 for the
genes downregulated by C/EBPb).
(B) Luciferase c/ebpb reporter assay. Lucifer-
ase activity is shown (mean of independent
duplicates ± SD), in relation with increasing
amounts of jun expression vector. Gray and
white boxes correspond to luciferase activity,
in the presence or absence of c/ebpb expres-
sion vector, respectively. All results corre-
spond to fold change induction, compared to
the basal luciferase activity in cells transfected
with the luciferase construct only. In the pres-
ence of c/ebpb expression vector, a clear and
regular decrease of luciferase activity is ob-
served when jun expression increases. West-
ern blots on the right, corresponding to the
gray boxes conditions, show that jun protein
expression increases without any modification
of the c/ebpb protein level (Anti-c/ebpb abcam
ab15050, dilution: 1/1000).a high-level amplification of jun on double-minute or
marker chromosomes (Figure 5C). As noted above, well-
differentiated human liposarcomas are characterized by
amplifications and overexpressions of MDM2 and CDK4
genes. CDK4 and CDK6 are closely related proteins that
play similar roles in cell-cycle progression by phosphory-
lating RB1. Despite the fact that the 3T3-L1 cell line is not
derived from a mouse tumor, it appears to be a highly
relevant cellular model of human liposarcoma.
3T3-L1 Cells Induce Liposarcoma-Like Tumors
in Nude Mice
It has been previously described that injection of 3T3-L1
and 3T3-F442A (another preadipocyte cell line) cells into
nude mice led to the development of flattened fat pads
(Fischbach et al., 2004; Green and Kehinde, 1979; Neels
et al., 2004). We injected 3 3 106, 6 3 106, and 10 3 106
3T3-L1 cells subcutaneously into the flank of athymic
female nude mice (two mice for each experimental
condition).
Four weeks after injection, we observed small subcuta-
neous tumors in all mice. These tumors grew progres-
sively, looking like the flattened fat pads previously
described. Finally, the tumors became more prominent,366 Cancer Cell 11, 361–374, April 2007 ª2007 Elsevier Inc.firmer, and much more vascular (Figure 6A). Two tumors
were removed at an early stage (fat-pad stage), two at
an intermediate stage, and two at a later stage (firm and
vascular stage). Macroscopic examination revealed that
most of these tumors contained different areas of more or
less firm tissue. Histopathological analysis showed two
components: a well-differentiated liposarcoma area (pre-
ponderant at the fat-pad stage), and an undifferentiated
area (preponderant at the late stage) (Figure 6B).
Immunohistochemistry revealed that the undifferenti-
ated area was strongly positive for Jun expression,
whereas the well-differentiated areas were negative
(Figure 6C). This suggested that the undifferentiated com-
ponent might be derived from the cells with high-level
amplification of jun described above in the wild-type
3T3-L1 cell line.
To verify this hypothesis, we performed a FISH analysis
of frozen and paraffin-embedded sections of the mouse
tumors. High-level amplification of jun was observed in
large nuclei from the undifferentiated areas of the tumors
(Figures 7A, 7B, and 7D), but not in nuclei from the well-dif-
ferentiated areas (Figures 7B and 7C), which exhibit only
mdm2 and cdk6 loci amplification. Short-term cultures
were performed on one undifferentiated mouse tumor,
Cancer Cell
JUN Amplification in Undifferentiated LiposarcomasFigure 5. Genomic Profile of the 3T3-L1
Cell Line
(A) CGH array profile of 3T3-L1 cell line
obtained on a home-made mouse array. Loci
corresponding to jun, cdk6, and mdm2 are
indicated. Chromosome numbers, x axis;
DNA ratios, y axis.
(B) Dual-color FISH on a 3T3-L1 metaphase.
The cdk6 probe is labeled in yellow, and the
mdm2 probe is labeled in pink. Single-color
images of the same mitosis are shown on the
right.
(C) High-level amplification of the jun locus
(yellow) can be observed by FISH in a small
percentage of nuclei.and metaphase spreads were obtained. FISH analysis
demonstrated a high-level genomic amplification of the
jun locus in all cells (Figure 7E). Jun overexpression wasalso confirmed by real-time PCR in all tumors; expression
was increased 16-fold, as a mean, compared to wild-type
3T3-L1 cells.Figure 6. Tumors Obtained after 3T3-L1
Injection in Nude Mice
(A) Representative tumors are shown at early
(left) and late (right) stages after 3T3-L1 cells
injection into nude mice.
(B) Histopathology reveals the presence of two
components in fat-pad tumors. The main part
of the tumors corresponds to a well-differenti-
ated adipose tissue, infiltrated by undifferenti-
ated cells. In late stage tumors, almost all the
cells are undifferentiated. For each stage, two
magnifications are shown.
(C) In fat-pad tumors, immunohistochemistry
reveals a strong Jun labeling in the undifferen-
tiated component (right), whereas well-differ-
entiated areas (left) were Jun negative. In
late-stage tumors, the main part of the tumor
appears uniformly undifferentiated and posi-
tive for Jun (two magnifications are shown).
Scale bar, 50 mm.Cancer Cell 11, 361–374, April 2007 ª2007 Elsevier Inc. 367
Cancer Cell
JUN Amplification in Undifferentiated LiposarcomasThese findings are in good agreement with the other
data presented above. They suggest that the 3T3-L1 cells
harboring high-level amplification of jun are selected in
vivo, and that they are associated with a more proliferative
and undifferentiated status. One cell line, LM3D, was es-
tablished from a late-stage mouse tumor. FISH analysis
of this cell line reveals a constant high-level amplification
of the jun locus. LM3D cell growth in vitro was compared
to that of the 3T3-L1 cell line. As shown in Figure 8A, the
proliferation rate was slightly lower for LM3D than for
Figure 7. FISH Experiments Performed on Tumors Obtained
after 3T3-L1 Cell Injection into Nude Mice
(A) Frozen tissue section from an undifferentiated tumor. The jun locus,
labeled in yellow, is highly amplified. The cdk4 locus, labeled in pink, is
a ploidy control locus, not amplified in the tumor.
(B) jun hybridization on a paraffin-embedded tissue section from a tu-
mor with well-differentiated area (right side), and undifferentiated area
(left side). The jun locus is amplified only in the undifferentiated area.
(C) Focus on the well-differentiated area from the same tumor as in (B),
with two jun loci in each nucleus.
(D) Focus on the undifferentiated area from the same tumor as in (B),
exhibiting high-level amplification of the jun locus in all nuclei.
(E) Short-term culture obtained from an undifferentiated late tumor.
One metaphase (left) and nuclei are shown. Jun locus is labeled in yel-
low. High-level amplification of jun as double-minute chromosomes is
observed in metaphase and interphase nuclei.368 Cancer Cell 11, 361–374, April 2007 ª2007 Elsevier Inc.3T3-L1, suggesting that the aggressiveness of LM3D-in-
duced tumors is not directly the consequence of a high
proliferation rate. In marked contrast with this anchor-
age-dependent proliferation, LM3D cells grown in soft
agar form more numerous, larger, and more invasive col-
onies than 3T3-L1 cells (Figure 8B). This suggests that
LM3D cells are associated with a tumorigenicity higher
than that of 3T3-L1 cells, a feature that could be a conse-
quence of jun overexpression, as recently described in hu-
man lung cancers (Maeno et al., 2006).
When grown to confluence and treated with ‘‘differenti-
ating medium’’ as previously described (Student et al.,
1980; Yeh et al., 1995), this cell line does not exhibit a ter-
minal adipocytic differentiation after oil red O stain (a spe-
cific lipid stain), contrary to the 3T3-L1 cell line grown in
the same conditions (Figure 8C). According to the hypoth-
esis that JUN overexpression blocks adipogenesis by in-
terfering with C/EBPb function and as observed in human
tumors, the differentiation process of LM3D, analyzed
by real-time PCR, is blocked before the induction of
C/EBPa (Figure 8D).
We then injected 6 3 106 LM3D cells to nude mice and
6 3 106 3T3-L1 cells to control mice. Three weeks after
injection, and contrary to control mice, which do not pres-
ent any sign of tumor development, all mice injected with
LM3D cells develop firm, vascular, and highly proliferative
tumors without any evidence of differentiation at histo-
pathological analysis. All the cells from these tumors
were strongly positive for Jun expression (data not
shown).
Overexpression of jun in 3T3-L1 Cells Delays Its
Inducible Adipocytic Differentiation
We then transfected a vector expressing jun into 3T3-L1
cells. A clone overexpressing jun (A3JUN), a control clone
containing the empty vector (A1CT), and wild-type 3T3-L1
cells were grown to confluence and then treated with ‘‘dif-
ferentiating medium.’’ We confirmed by FISH that the
A3JUN clone was established from a 3T3-L1 cell without
endogenous Jun amplification (data not shown). As early
as the second day after induction, massive adipocyte dif-
ferentiation was observed by oil red O stain in the A1CT
control clone and in 3T3-L1 wild-type cells, whereas no
labeling was detected at this stage in A3JUN cells
(Figure 8E). When maintained for a further 4 days at con-
fluence in differentiating medium, the A3JUN cells began
to slightly differentiate (Figure 8E), suggesting that adipo-
cyte differentiation was blocked or largely delayed in this
clone.
Role of JUN in Oncogenesis and Differentiation
JUN oncoprotein plays multiple roles at the interface be-
tween cell proliferation and differentiation. Jun overex-
pression is not oncogenic alone in transgenic mice (Gri-
goriadis et al., 1993); nevertheless, its viral homolog
v-Jun induces fibrosarcomas in chicken (Cavalieri et al.,
1985; Maki et al., 1987) and wound-induced tumors in
transgenic mice (Schuh et al., 1990). In human, JUN
overexpression without a concomitant increase of its
Cancer Cell
JUN Amplification in Undifferentiated LiposarcomasFigure 8. Differentiation of Adipocyte Cell Lines In Vitro
(A) LM3D cell line, established from a late-stage mouse tumor, was grown in parallel to 3T3-L1 cells, and their growth was assessed over a 5 day time
course (mean of triplicates ± SD).
(B) LM3D cells (overexpressing jun) and 3T3-L1 cells were plated in soft-agar assays and allowed to grow for 4 weeks. Colonies were two times more
numerous, larger, and irregular in LM3D wells. The insets show a magnification of the colonies.
(C) LM3D cell line was grown to confluence and treated with differentiating medium. This cell line (bottom) does not exhibit adipocytic differentiation
(oil red O staining) after 6 days of treatment (D6), contrary to the 3T3-L1 cell line (top).
(D) Expression levels of jun and of the main adipogenesis genes in 3T3-L1 and LM3D cell lines (mean of independent duplicates, ± SD). In LM3D cell
line, adipogenesis process is blocked before the induction of C/EBPa by C/EBPb, as observed in human tumors.
(E) The A1CT control clone (top) is transfected with empty vector. Its differentiation into adipocytes (oil red O staining) starts 2 days (D2) after stim-
ulation by the differentiating treatment. In the A3JUN clone (bottom), which is transfected with the vector expressing jun, differentiation is delayed,
starting only at day 6 (D6).Cancer Cell 11, 361–374, April 2007 ª2007 Elsevier Inc. 369
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JUN Amplification in Undifferentiated Liposarcomasphosphorylation has been described in some tumors (Ma-
thas et al., 2002; Rangatia et al., 2003). In these tumors, as
well as in undifferentiated liposarcomas, enhanced JUN
transcription activity may be the consequence of titration
of its repressor complex by an increase in JUN protein
level, as recently suggested (Weiss and Bohmann, 2004).
Furthermore, it has been recently described that intestinal
tumorigenesis is increased by c-Jun phosphorylation
(Nateri et al., 2005). It has also been demonstrated that
Jun stimulates angiogenesis, through proliferin activation,
in a cell model of fibrosarcoma (Toft et al., 2001).
The data provided here demonstrate that amplification
and overexpression of JUN block adipocytic differentia-
tion at an early step and is associated with a much more
aggressive phenotype in corresponding tumors. In human
sarcomas, its overexpression likely blocks the adipocytic
differentiation of human liposarcomas with 12q14 amplifi-
cation, leading to more aggressive undifferentiated tu-
mors. To our knowledge, JUN amplification has not previ-
ously been described in a human tumor (Jochum et al.,
2001; Vogt, 2001). Only few data on the role of JNK-JUN
pathway activation in adipogenesis are available; JNK ac-
tivation blocks adipogenesis through PPARg phosphory-
lation (Adams et al., 1997; Camp and Tafuri, 1997; Camp
et al., 1999; Hu et al., 1996). It has also been reported that
JNK negatively regulates adipocyte differentiation from
human mesenchymal stem cells through CREB down-
regulation (Tominaga et al., 2005). Nevertheless, other data
suggest that JNK1 pathway inactivation could interfere
with formation of subcutaneous fat in obese mice, sug-
gesting that JNK1 activation could also, in some in-
stances, accelerate fat deposition (Hirosumi et al., 2002).
However, in this mouse model, it is not clear whether the
effect is on the adipocyte differentiation or on energy me-
tabolism. Our previous results obtained on sarcomas with
amplification/overexpression of MAP3K5, an upstream
activator of JNK, are in agreement with a negative role of
JNK1 on adipocyte differentiation (Chibon et al., 2004).
The present results demonstrate that overexpression of
JUN, a downstream target of the JNK pathway, leads to
a similar negative regulation of adipogenesis. As indicated
above, the overexpression of DeltaFosB decreases adipo-
genesis by interfering with C/EBPb function (Sabatakos
et al., 2000). This feature, which is reminiscent of what we
have observed in undifferentiated human liposarcomas
and in the mouse LM3D cell line, suggests that JUN over-
expression might block adipogenesis in human tumors
through an interaction with C/EBPb. Finally, it is also
of interest to note that late-stage tumors obtained after
3T3-L1 injection in nude mice appear more vascular, a
feature which could be related to the induction of
angiogenesis by Jun, as previously described (Toft et al.,
2001).
The molecular data presented in this study suggest that,
in human sarcomas, JUN overexpression could interfere
with adipocytic differentiation. The cellular and xenograft
models described here would be particularly efficient tools
for the analysis of the connections between oncogenesis
and differentiation in sarcomas.370 Cancer Cell 11, 361–374, April 2007 ª2007 Elsevier Inc.EXPERIMENTAL PROCEDURES
Tumor Samples
Tumors T1–T10 and T14–T16 were classified as undifferentiated
sarcomas by the pathologists of the French Sarcoma Group. All
these tumors were associated with a MIB1 positivity in more than
10% of the cells (range: 10%–70%). All but one were negative for
BCL2 labeling. Tumors T11–T13 correspond to well-differentiated
liposarcomas. All these WDLPS were positive for MIB1 in less than
5% of the cells, and negative for BCL2 labeling. The mean age of
the patients was 65. All tumors except two were localized in
retroperitoneum. According to French law at the time of the study,
the tumor samples were collected in agreement with the ANAES
recommendations. Informed consent was obtained from all patients.
Experiments were performed in agreement with the Bioethics Law n
2004-800, and the Ethics Charter from the National Institute of Cancer
(INCa).
Human Array CGH
DNA from BACs (bacterial artificial chromosomes) and PACs (P1-de-
rived artificial chromosomes) were obtained after isolation of one bac-
terial colony and amplification by Qiagen Plasmid Maxi Kit, using the
conditions of low-copy-number plasmids. The genomic location of
BACs or PACs was checked by hybridization on normal metaphase
spreads. Sonicated BACs and PACs were spotted in duplicate on
Corning Ultragaps slides in 75% formamide (37 BACs/PACs located
in the 1p32 band, 56 in the 6q23 band, and 29 in the 12q14 band). After
rehydration and UV fixation, slides were blocked for 15 min with suc-
cinic anhydride/1-methyl 2-pyrrolidinone/sodium borate pH8 solution.
Slides were denatured for 2 min in boiling water, dehydrated in 95%
ethanol, and dried by centifugation at 400 rpm.
After DpnII digestion (Biolabs) and purification with PCR Purification
Kit (Qiagen), 1.5 mg of tumor DNA and 1.5 mg of normal DNA were la-
beled, respectively, with dCTP-Cy5 or dCTP-Cy3 (Amersham) by ran-
dom priming (BioPrime DNA Labeling System Kit, Invitrogen). The re-
action was performed at 37C for 3 hr. After purification on microcon
YM30 (Millipore) and denaturation at 92C, these DNAs were prehybri-
dized with 200 mg of Cot-1 DNA (Roche) for 30 min at 37C in 15 ml of
hybridization buffer (50% formamide, 40 mM NaH2PO4, 0.1% SDS,
10% dextran sulfate, 23 SSC, Denhardt’s solution) and put on treated
microarray slides. After 24 hr hybridization at 37C, slides were
washed for 5 min in 0.53 SSC, 0.03% SDS at 65C, and for 5 min in
0.53 SSC, 0.03% SDS at 45C. After drying by centrifugation,
slides were read with GenePix 4000B scanner (Axon Instruments).
Results were analyzed with GenePix Pro 5.1 software. To normalize
data, we used 6q23 spots, which have normal genomic status in these
tumors.
Mouse Array CGH
A homemade genome-wide mouse BAC array was built in the labora-
tory. This array contains 696 BACs that were isolated, validated by
end-sequencing, and amplified by multiple displacement amplifica-
tion. The collection was spotted in quadruplicate in 75% formamide
on Corning Ultragaps slides. We used this array in the same way as
we used human CGH array, but replacing human Cot-1 by mouse
Cot-1 and normal human DNA by normal mouse liver DNA.
FISH on Metaphase Spreads, Frozen Tissue Sections,
and Paraffin Sections
Metaphase spreads were obtained by standard procedures. For
frozen tissues, 5 mm thick tumor sections were used. Before denatur-
ation, slides were treated for 10 min in 23 SSC and dehydrated in
successively increasing concentrations of ethanol (70%, 90%, and
100%), 5 min each. For paraffin sections, slides were treated by the
Zymed conversion kit, according to the manufacturer’s protocol.
BAC and PAC labeling by nick-translation, denaturation, and
detection were achieved as previously described (Schleiermacher
et al., 2004).
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Total tumor RNAs were extracted either from frozen tumor samples or
from cell lines by Trizol extraction (Life Technologies, Inc., Rockville,
MD). To eliminate DNA contamination, RNAs were treated with RNase-
free DnaseI (Roche): 3 mg of RNA was treated with 10 U of DNase
in DNase buffer (Invitrogen). The reaction was performed at 37C for
30 min and stopped by the addition of 1 ml of 25 mM EDTA and heating
for 10 min at 65C. The RNA was reverse transcribed into cDNA with
the GeneAmp RNA PCR Core Kit (Applied Biosystems). Real-time
PCR was performed with SYBR Green Master Mix (Applied Biosys-
tems). Human JUN primers were previously described (Jean et al.,
2001). Forward and reverse primers were as follows: 50-CACGTTAA
CAGTGGGTGCCA-30 and 50-CCCCGACGGTCTCTCTTCA-30 for
human JUN; 50-CTTCAACAGCGACACCCACT-30 and 50-GTGGTCCA
GGGGTCTTACTC-30 for human GAPDH; 50-AACGCCATTGAGAAG
CGCTA-30 and 50-GCAAGACAGCAGATTTATTCAG-30 for human
SREBP1; 50-CAGGTCAAGAGCAAGGCCAA-30 and 50-CGCACGGC
GATGTTGTTGC-30 for human C-EBPb; 50-GACCTAGAGATCTGGCT
GTG-30 and 50-GATGGACTGATCGTGCTTCG-30 for human C-EBPa;
50-CTGTCTGCAAACATATCACAAG-30 and 50-GGAGTGGTCTTC
CATTACGG-30 for human PPARg2; 50-ATCACCGAGCGCTTGAT
GTG-30 and 50-CTTCTTGCGGTTGCCGCAAA-30 for human ADIPSIN;
50-GGACAATGTCCATCTCTTGG-30 and 50-GTAAGACGTCTACAAAA
TCTGC-30 for human LPL; 50-AGTCATGAACCACGTTAACAG-30 and
50-AGCCCTGACAGTCTGTTCTC-30 for murine jun; 50-AAAATGGTG
AAGGTCGGTGT-30 and 50-TGACTGTGCCGTTGAATTTG-30 for mu-
rine gapdh; 50-AGAAGCGCACAGCCCACAAT-30 and 50-GCAAGACA
GCAGATTTATTCAG-30 for murine srebp1; 50-CCAAGGCCAAGGCC
AAGAAG-30 and 50-TGCGCACCGCGATGTTGTTG-30 for murine
c-ebpb; 50-AGTCGGTGGACAAGAACAGC-30 and 50-ACTCCAGCACCT
TCTGTTGC-30 for murine c-ebpa; 50-GCTGTTATGGGTGAAACTCT-30
and 50-TGGCATCTCTGTGTCAACCA-30 for murine pparg2; 50-CGGG
GTAGTCACCATTAACA-30 and 50-CTTTTTGCCATTGCCACAGA-30
for murine adipsin; 50-TAGACAACGTCCACCTCTTAG-30 and 50-
GTAAGACATCTACAAAATCAGC-30 for murine lpl; 50-CAATGACAT
TTCACACACGCAG-30 and 50-GCTGGTGAGGACCTGTTGAT-30 for
murine leptin.
All the real-time PCR annealing and extension were performed at
60C. Each reaction was performed in duplicate.
To normalize the data, we used the GAPDH genes as reference
genes. Human tumor data were normalized against an RNA pool of
two well-differentiated liposarcomas in which the JUN expression level
is basal. For murine cell-line analyses, data were normalized against
wild-type 3T3-L1 at day 0 before addition of the differentiating me-
dium. The results were calculated as previously described (De Preter
et al., 2002).
Western Blot
Total proteins were extracted by crushing frozen tumor samples in 23
Laemmli buffer. Extracts were probed with a primary anti-c-JUN anti-
body (H79) (Santa Cruz Biotechnology) or anti-b-actin antibody
(Sigma-Aldrich) at a dilution of 1:500 and 1:10,000, respectively.
Anti-phospho-jun antibody was kindly provided by F. Mechta-Grigor-
iou (Lallemand et al., 1998) and used at a dilution of 1:200. Anti-SAPK/
JNK and phospho-SAPK/JNK (Cell Signaling) were used at a dilution of
1:200. The secondary antibodies were horseradish peroxidase-conju-
gated anti-rabbit or anti-mouse (APBiotech), as appropriate, and the
signal was detected by enhanced chemiluminescence (SuperSignal
West Pico Chemiluminescent substrate, Pierce). Western blot images
were acquired with a FUJIFILM luminescent image LAS-1000plus
analyzer. They were analyzed with Image Gauge v 4.0 software, which
allowed us to normalize JUN expression data to b-actin expression
values.
Immunohistochemistry
Immunohistochemistry was performed in all cases on a representative
paraffin block with anti-JUN antibody (H79) at a dilution of 1:1000,
according to the method described previously (Coindre et al., 2003).Transcriptome Analysis
RNA quality was checked on an Agilent 2100 bioanalyzer (Agilent
Technologies). Samples were then analyzed on Human Genome
U133 Plus 2.0 chip (Affymetrix), according to the manufacturer’s
procedures. Data were normalized using the DChip software.
Reporter Gene Assay
Experiments were performed twice on NIH-3T3 cells. Briefly, 105 cells
were seeded in duplicate in 12-well plates in DMEM (Gibco) plus 10%
fetal bovine serum (Gibco). One day later, 50 ng of a c/ebpb expression
plasmid (pcDNA3-C/EBPb [Zhu et al., 2002]), 750 ng of a promoter re-
porter construct containing part of the c/ebpb responsive Id2 gene
fused with the luciferase gene (pGL2-Id2/E [Karaya et al., 2005]), in-
creasing amounts (from 250 to 1250 ng) of a jun expression plasmid
(RSV-jun; Pfarr et al., 1994), and 5 ng of pRL-SV40 Renilla luciferase
control were transfected in each well, with Effecten transfection re-
agents (Qiagen). The total amount of DNA among all conditions was
kept constant by adding RSV-bgal plasmid DNA. Using the Dual-Lucif-
erase reporter assay system (Promega), total cell lysates were pre-
pared 48 hr after transfection, and luciferase assays were performed
according to the manufacturer’s instructions.
Tumor Xenografts
We injected 33 106, 63 106, and 103 106 native 3T3-L1 cells subcu-
taneously into the flank of 8-week-old athymic female nude mice (two
mice for each experimental condition). Two mice were sacrificed at an
early stage, two were sacrificed at an intermediate stage, and two were
sacrificed at a late stage. For each case, we froze and studied inde-
pendently tumor fragments with macroscopically different appear-
ances. All the tumors were analyzed by CGH-array, FISH, and immu-
nohistochemistry. Experiments were performed in accordance with
relevant institutional guidelines from the Direction De´partementale
des Services Ve´te´rinaires de Paris (approval B750518).
Preparation of a Stable Cell Line
The 3T3-L1 cell line was graciously provided by B. Feve (Mercier et al.,
2001). 3T3-L1 cells were seeded at a density of 4.3 3 105 per 10 cm
diameter culture dish in DMEM (Gibco) plus 10% donor calf serum
(Gibco). After 48 hr, cells were transfected with 10 mg of plasmid over-
expressing jun, or of a control plasmid, in the presence of 30 ml of Lip-
ofectamine (Invitrogen). These plasmids were generously provided by
F. Mechta-Grigoriou (Pfarr et al., 1994). In the plasmid overexpressing
jun, the murine jun cDNA is cloned downstream of the Moloney murine
leukemia virus long terminal repeat and the neor selection gene down-
stream of the metallothionein promoter. The control plasmid contains
only the Moloney murine leukemia virus long terminal repeat and the
neor selection gene downstream of the metallothionein promoter. After
24 hr, 800 mg/ml G418 was added to the medium. Individual clones
were picked and characterized by real-time PCR.
Oil Red O Staining
After three washes in 13 PBS, cells were fixed with 3.7% formalde-
hyde (Sigma) for 5 min at room temperature. After a second wash, cells
were stained with a filtered solution of 0.3% oil red O for 30–40 min.
Finally, cells were washed three times with water.
Proliferation and Soft-Agar Assays
For proliferation rate assays, 2 3 104 cells were seeded in 24-well
plates in DMEM (Gibco) plus 10% donor calf serum (Gibco). Cells
from triplicates were counted every day with a Z2 Coulter counter
(Beckman Coulter).
Soft-agar assays were performed in duplicates. For these assays,
1 3 104 cells were added to 1 ml of growth medium with 0.3% agar
and layered onto 1 ml of 0.3% agar beds in 6-well plates. Colonies
were photographed and counted in four independent wells.Cancer Cell 11, 361–374, April 2007 ª2007 Elsevier Inc. 371
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